Will FDA Budge On User Fee Hike Reductions? Stakeholders To Meet In May
This article was originally published in The Gray Sheet
Executive SummaryThe current preoccupation with FDA postmarket safety on Capitol Hill could dispose legislators toward the agency's stance that year-over-year user fee hikes should not be held to the inflationary rate alone
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.